1. Home
  2. PD vs BBIO Comparison

PD vs BBIO Comparison

Compare PD & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PagerDuty Inc.

PD

PagerDuty Inc.

HOLD

Current Price

$13.14

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$75.82

Market Cap

14.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PD
BBIO
Founded
2009
2015
Country
United States
United States
Employees
1242
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
14.7B
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
PD
BBIO
Price
$13.14
$75.82
Analyst Decision
Buy
Strong Buy
Analyst Count
10
21
Target Price
$17.70
$76.24
AVG Volume (30 Days)
2.1M
1.8M
Earning Date
11-25-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.63
N/A
Revenue
$489,207,000.00
$353,780,000.00
Revenue This Year
$8.16
$127.64
Revenue Next Year
$3.88
$78.38
P/E Ratio
$8.08
N/A
Revenue Growth
7.01
62.46
52 Week Low
$11.13
$27.23
52 Week High
$20.00
$78.44

Technical Indicators

Market Signals
Indicator
PD
BBIO
Relative Strength Index (RSI) 47.27 62.87
Support Level $12.69 $75.82
Resistance Level $13.11 $78.44
Average True Range (ATR) 0.36 2.20
MACD 0.14 -0.24
Stochastic Oscillator 84.08 68.91

Price Performance

Historical Comparison
PD
BBIO

About PD PagerDuty Inc.

PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: